Information Provided By:
Fly News Breaks for August 22, 2019
CLSD
Aug 22, 2019 | 15:16 EDT
JMP Securities analyst Donald Ellis reiterated an Outperform rating on Clearside Biomedical, but it lowering his price target on shares to $3 from $4 after the FDA requested additional stability data for Xipere, which will delay a final FDA approval and require an NDA re-submission in Q1 of 2020. Ellis added that he now sees Xipere approval in Q3 of 2020.
News For CLSD From the Last 2 Days
There are no results for your query CLSD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.